Articles by Adeline Siew - BioPharm International



Articles by Adeline Siew

Shire to Acquire SARcode for $160 Million

Mar 27, 2013

Shire has announced plans to acquire dry eye specialist SARcode Bioscience with the aim of expanding its ophthalmics portfolio. Under the terms of the agreement, Shire will pay $160 million upfront and SARcode shareholders will receive additional undisclosed payments upon achievement of certain clinical, regulatory and/or commercial milestones.

Roche and BioLamina Collaborate on Novel Cell Culture Systems

Mar 6, 2013

Roche and BioLamina have entered into a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will assess laminin-based in-vitro cell culture matrices that can offer physiological microenvironments for living cells.

First Biologic Approved in the EU for Gouty Arthritis

Mar 6, 2013

Ilaris (canakinumab), a selective, fully human, monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), has been approved in the EU for symptomatic pain relief in patients suffering from gouty arthritis whose condition cannot be managed with current treatments.

Ablynx and Spirogen Collaborate on Novel Toxin-Nanobody Drug Conjugates

Feb 27, 2013

Belgium drug developer Ablynx and UK-based Spirogen have entered into a research collaboration to discover and develop novel anticancer drug conjugates combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBDs), and the company,s associated linker technology, with nanobodies generated using Ablynx's proprietary technology platform.

Sanofi's Six-In-One Pediatric Vaccine Recommended for European Approval

Feb 26, 2013

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's six-in-one pediatric vaccine for marketing authorization.

Merck's Cilengitide Fails to Meet Primary Endpoint in Phase III Trial

Feb 25, 2013

Merck's investigational integrin inhibitor cilengitide did not meet its primary endpoint in the CENTRIC Phase III trial evaluating if the agent could prolong overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy).

Merck Pays $688 Million to Resolve Vytorin Lawsuits

Feb 18, 2013

Merck has agreed in principle to pay $688 million to settle two federal securities class-action lawsuits involving the company's anticholesterol drugs Vytorin and Zocor, thereby avoiding trial.

First Commercially Available Intravenous Immune Globulin with a Thrombin Generation Assay Test

Feb 6, 2013

Biotest Pharmaceuticals Corporation announced that Bivigam [immune globulin intravenous (human), 10% liquid] is now available in the pharmaceutical distribution channel for use by physicians, pharmacists and hospitals throughout the US. Bivigam is a sugar-free, glycine stabilized intravenous immune globulin that has been approved by the FDA in December 2012 for the treatment of patients with primary humoral immunodeficiency (PI).

Shire to Resolve Federal Investigation and Pay $57.5 Million

Feb 5, 2013

Shire announced that it has reached an agreement in principle with the US government to resolve the previously disclosed civil investigation into its sales and marketing practices in the US relating to the company?s attention deficit hyperactivity disorder (ADHD) drugs, Adderall XR and Vyvanse as well as the ADHD patch Daytrana.



Click here